Ackerman Cancer Center, a leading institution in personalized oncology care, is proud to announce its adoption of MyoStrain, a cutting-edge cardiac assessment technology. This partnership underscores Ackerman Cancer Center’s commitment to providing state-of-the-art care and prioritizing the overall health and wellness of its patients.
HealthTech Insights: New Professional Physical Therapy Clinic Brings Expert Care to Northport Community
Myostrain, developed by Myocardial Solutions, is enhanced cardiac software that provides novel clinical information to help physicians risk stratify, detect and manage cardiac dysfunction from patients at risk of heart failure and oncological patients at risk of cardio toxicity from cancer treatments in 10 minutes. MyoStrain is particularly valuable for cancer patients, as it provides early detection and helps physicians prevent cardiac dysfunction related to cancer treatments such as chemotherapy and radiation. By leveraging MyoStrain, Ackerman Cancer Center aims to proactively monitor and protect heart health throughout a patient’s treatment journey.
We are excited to be the first center in Florida to offer Cardiac MRI scans with MyoStrain. This will allow us to closely monitor the patient’s heart during their cancer treatment.
HealthTech Insights: Environmental Sustainability and the Supply of Medicines for Clinical Trials, Upcoming Webinar Hosted by Xtalks
Enhanced Care for Cancer Patients
The integration of MyoStrain into Ackerman Cancer Center’s clinical protocols ensures that patients receive comprehensive care. Cancer therapies, while lifesaving, can pose risks to cardiovascular health. MyoStrain’s ability to detect subtle changes in cardiac performance allows clinicians to tailor treatment plans, minimize risks, and improve long-term outcomes for patients.
HealthTech Insights: Dr. Shaina Kumar Joins OCLI Vision as Newest Ophthalmologist
Dr. Ackerman stated, “We are excited to be the first center in Florida to offer Cardiac MRI scans with MyoStrain. This will allow us to closely monitor the patient’s heart during their cancer treatment.”
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source – prweb
